European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
It is well demonstrated that Her-2 positive breast cancer patients have more aggressive disease, with a poor prognosis. The author report the case of a 50-year-old Caucasian woman, diagnosed with a seven-centimeter right breast cancer. Biospy core revealed a Her-2 positive, positive for hormonal receptors, ki67 at 70%, breast invasive ductal carcinoma, associated with right axillary adenomegalies. Positron emission tomography scan showed diffuse metastatic adenomegalies upper and under the diaphragm and a 55×55 mm lesion in the right breast. The patient began chemotherapy with docetaxel+pertuzumab+trastuzumab regimen. After three courses, all the positron emission tomography scans did not show any pathological hypermetabolism and the primitive lesion was measured at 16×18 mm. It was decided to perform a right mastectomy. The patient will then follow maintenance with pertuzumab and trastuzumab, in combination with hormonotherapy.